Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207725 · ClinicalTrials.gov registry record · Phase 3
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
A Phase 3 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT02207725 is a Phase 3 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT02207725, a Phase 3 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
Interventions
- OTHER Placebo
- BIOLOGICAL Andexanet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207725
The ClinicalTrials.gov registry entry for NCT02207725 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02207725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207725 about?
NCT02207725 is a clinical study titled "A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban". The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
What is the current status of trial NCT02207725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2014-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02207725?
The interventions under investigation include: Placebo (OTHER), Andexanet (BIOLOGICAL).
Who is sponsoring clinical trial NCT02207725?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.